Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
NEW YORK, Aug. 23, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Envision Healthcare Corporation (NYSE:EVHC) who purchased shares between March 2, 2015 and July 21, 2017. The action, which was filed in the United States District Court for the Middle District of Tennessee, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Envision Healthcare subsidiary EmCare Holdings, Inc. routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.
Shareholders have until October 3, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/envision-healthcare-corporation?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
